OBJECTIVES: To assess the diagnostic accuracy of serum bone turnover markers for detection of bone metastasis in patients with prostate cancer (PCa) and to assess the usefulness of these markers as predictors of mortality from PCa. METHODS: Serum total alkaline phosphatase, bone-specific alkaline phosphatase, carboxy-terminal pyridinoline cross-linked telopeptide parts of type-I collagen (1CTP), tartrate-resistant acid phosphatase type 5 b, and prostate-specific antigen (PSA) levels were measured in 222 patients (58 with bone metastasis, 57 with T2M0 PCa, 55 with T3M0 PCa, and 52 without PCa). Multivariate stepwise logistic regression analysis was used to identify independent predictors of bone metastasis. Correlation of serum marker levels with bone metastasis was assessed using receiver operating characteristics analysis. Multivariate Cox proportional hazards analysis was used to predict cause-specific survival in PCa patients with bone metastasis. RESULTS: Serum total alkaline phosphatase, bone-specific alkaline phosphatase, 1CTP, tartrate-resistant acid phosphatase type 5 b, and PSA levels were significantly elevated in patients with bone metastasis, and correlated significantly with the extent of disease on bone scintigraphy. Multivariate stepwise logistic regression analysis demonstrated that serum PSA and 1CTP were significant predictors of bone metastasis. Receiver operating characteristics analyses showed that serum 1CTP level was the most reliable predictor of bone metastasis (area under the curve = 0.85). Multivariate Cox proportional hazards analysis revealed that only serum 1CTP was an independent prognostic factor for PCa-related death. CONCLUSIONS: Serum 1CTP level was a more reliable marker than the others to detect bone metastatic spread and to predict survival probability in PCa patients with bone metastasis. Copyright (c) 2010 Elsevier Inc. All rights reserved.
OBJECTIVES: To assess the diagnostic accuracy of serum bone turnover markers for detection of bone metastasis in patients with prostate cancer (PCa) and to assess the usefulness of these markers as predictors of mortality from PCa. METHODS: Serum total alkaline phosphatase, bone-specific alkaline phosphatase, carboxy-terminal pyridinoline cross-linked telopeptide parts of type-I collagen (1CTP), tartrate-resistant acid phosphatase type 5 b, and prostate-specific antigen (PSA) levels were measured in 222 patients (58 with bone metastasis, 57 with T2M0 PCa, 55 with T3M0 PCa, and 52 without PCa). Multivariate stepwise logistic regression analysis was used to identify independent predictors of bone metastasis. Correlation of serum marker levels with bone metastasis was assessed using receiver operating characteristics analysis. Multivariate Cox proportional hazards analysis was used to predict cause-specific survival in PCa patients with bone metastasis. RESULTS: Serum total alkaline phosphatase, bone-specific alkaline phosphatase, 1CTP, tartrate-resistant acid phosphatase type 5 b, and PSA levels were significantly elevated in patients with bone metastasis, and correlated significantly with the extent of disease on bone scintigraphy. Multivariate stepwise logistic regression analysis demonstrated that serum PSA and 1CTP were significant predictors of bone metastasis. Receiver operating characteristics analyses showed that serum 1CTP level was the most reliable predictor of bone metastasis (area under the curve = 0.85). Multivariate Cox proportional hazards analysis revealed that only serum 1CTP was an independent prognostic factor for PCa-related death. CONCLUSIONS: Serum 1CTP level was a more reliable marker than the others to detect bone metastatic spread and to predict survival probability in PCa patients with bone metastasis. Copyright (c) 2010 Elsevier Inc. All rights reserved.
Authors: Yu Zheng; Dennis Basel; Shu-Oi Chow; Colette Fong-Yee; Sarah Kim; Frank Buttgereit; Colin R Dunstan; Hong Zhou; Markus J Seibel Journal: Clin Exp Metastasis Date: 2014-09-16 Impact factor: 5.150
Authors: A Alcaraz; R González-López; J Morote; C de la Piedra; C Meseguer; E Esteban; M Climent; B González-Gragera; J-L Alvarez-Ossorio; I Chirivella; B Mellado; P-C Lara; F Vázquez; J-A Contreras; J Carles; A Murias; V Calderero; J Comet-Batlle; A González-Del Alba; L León-Mateos; A Mañas; J Segarra; A Lassa; C González-Enguita; M-J Méndez; P Samper; M Unda; I Mahillo-Fernández; J Bellmunt Journal: Br J Cancer Date: 2013-06-25 Impact factor: 7.640
Authors: Harald Rief; Georg Omlor; Michael Akbar; Thomas Bruckner; Stefan Rieken; Robert Förster; Ingmar Schlampp; Thomas Welzel; Tilman Bostel; Heinz Jürgen Roth; Jürgen Debus Journal: BMC Cancer Date: 2016-03-17 Impact factor: 4.430
Authors: Sun Min Lim; Youn Nam Kim; Ki Hyun Park; Beodeul Kang; Hong Jae Chon; Chan Kim; Joo Hoon Kim; Sun Young Rha Journal: BMC Cancer Date: 2016-07-04 Impact factor: 4.430